Subscribe to RSS
DOI: 10.1055/s-2003-37590
Natural History and Prognosis of Hepatitis B
Publication History
Publication Date:
03 March 2003 (online)
![](https://www.thieme-connect.de/media/sld/200301/lookinside/thumbnails/10.1055-s-2003-37590-1.jpg)
ABSTRACT
The natural history of hepatitis B virus (HBV) infection is complex and variable and is greatly influenced by the age at infection, the level of HBV replication, and host immune status. Chronic HBV infection generally consists of an early replicative phase with active liver disease (hepatitis B e antigen [HBeAg]-positive chronic hepatitis) and a late low or nonreplicative phase with HBeAg seroconversion and remission of liver disease (inactive carrier state). After HBeAg seroconversion, some patients may have active hepatitis due to HBV variants not expressing HBeAg (HBeAg-negative chronic hepatitis). Morbidity and mortality are linked to development of cirrhosis and hepatocellular carcinoma. Survival is reasonably good (about 85% probability at 5 years) in compensated cirrhosis but very poor in decompensated cirrhosis. Both cirrhotic and noncirrhotic patients with sustained reduction of HBV replication and normalization of aminotransferase after interferon alfa therapy have a reduced risk for liver-related complications.
KEYWORDS
Hepatitis B virus - chronic hepatitis B - interferon alfa
REFERENCES
- 1 Maddrey W C. Hepatitis B: an important public health issue. J Med Virol . 2000; 61 362-366
- 2 Lee W M. Hepatitis B virus infection. N Engl J Med . 1997; 337 1733-1745
- 3 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology . 2001; 120 1828-1853
- 4 Lok A SF, McMahon B J. Chronic hepatitis B. Hepatology . 2001; 34 1225-1241
- 5 Milich D R, Chen M K, Hughes J L, Jones J E. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol . 1998; 160 2013-2021
- 6 Hadziyannis S J, Vassilopoulos D. Hepatitis B e antigen- negative chronic hepatitis B. Hepatology . 2001; 34 617-624
- 7 Chemin I, Zoulim F, Merle P. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol . 2001; 34 471-473
- 8 Kawatani T, Suou T, Tajima F. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol . 2001; 67 45-50
- 9 McMahon B J, Alward W LM, Hall D B. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis . 1985; 151 599-603
- 10 Smedile A, Farci P, Verme G. Influence of delta infection on severity of hepatitis B. Lancet . 1982; 2 945-947
- 11 Feray C, Gigou M, Samuel D. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology . 1993; 104 549-555
- 12 Chang M H. Natural history of hepatitis B infection in children. J Gastroenterol Hepatol . 2000; 15(Suppl) E11-E19
- 13 Tassopoulos N C, Papaevangelou G J, Sjogren M H. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology . 1987; 92 1844-1850
- 14 Burk R D, Hwang L Y, Ho G YF, Shafritz D A, Beasley R P. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis . 1994; 170 1418-1423
- 15 Cacciola I, Cerenzia G, Pollicino T. Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol . 2002; 36 426-432
- 16 Lok A SF, Lai C L, Wu P C, Leung E KY, Lam T S. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology . 1987; 92 1839-1843
- 17 Realdi G, Alberti A, Rugge M. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology . 1980; 79 195-199
- 18 Hoofnagle J H, Dusheiko G M, Seef L B. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med . 1981; 94 744-748
- 19 Fattovich G, Rugge M, Brollo L. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology . 1986; 6 167-172
- 20 Liaw Y F, Tai D I, Chu C M, Chen T J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology . 1988; 8 493-496
- 21 Moreno-Otero R, Garcia-Monzòn C, Garcia-Sànchez A. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. Am J Gastroenterol . 1991; 86 560-564
- 22 Zarski J P, Marcellin P, Cohard M. Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. J Hepatol . 1994; 20 636-640
- 23 Di Marco V, Lo Iacono O, Cammà C. The long-term course of chronic hepatitis B. Hepatology . 1999; 30 257-264
- 24 Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology . 1999; 29 971-975
- 25 Yuen M F, Hui C K, Cheng C C. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology . 2001; 34 139-145
- 26 Chang M H, Hsu H Y, Hsu H C. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology . 1995; 22 1387-1392
- 27 Bortolotti F, Jara P, Crivellaro C. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol . 1998; 29 184-190
- 28 Hsu Y S, Chien R N, Yeh C T. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology . 2002; 35 1522-1527
- 29 Fong T L, Di Bisceglie M A, Gerber M A, Waggoner J G, Hoofnagle J H. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology . 1993; 18 1313-1318
- 30 McMahon B J, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med . 2001; 135 759-768
- 31 Bortolotti F, Cadrobbi P, Crivellaro C. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology . 1990; 99 805-810
- 32 Wong D KH, Cheung A M, O'Rourke K. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med . 1993; 119 312-323
- 33 Vajro P, Migliaro F, Fontanella A, Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg . 1998; 61 219-223
- 34 Chang M H, Sung J L, Lee C Y. Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. J Pediatr . 1989; 115 385-390
- 35 Alward W LM, McMahon B J, Hall D B. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis . 1985; 151 604-609
- 36 Liaw Y F. Current trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol . 1997; 12 S346-S353
- 37 Perillo R P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology . 2001; 120 1009-1022
- 38 Orito E, Mizokami M, Sakugawa H. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotype B and C. Japan HBV Genotype Research Group. Hepatology . 2001; 33 218-223
- 39 Chu C J, Hussain M, Lok A SF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared to hepatitis B virus genotype C. Gastroenterology . 2002; 122 1756-1762
- 40 Chan H LY, Leung N WY, Hussain M, Wong M L, Lok A SF. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology . 2000; 31 763-768
- 41 Funk M L, Rosenberg D M, Lok A SF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat . 2002; 9 52-61
- 42 Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol . 2000; 61 398-402
- 43 Fattovich G, Farci P, Rugge M. Randomized controlled trial of lymphoblastoid interferon alfa in patients with chronic hepatitis B who lacked hepatitis B e antigen. Hepatology . 1992; 15 584-589
- 44 Lampertico P, Del Ninno E, Manzin A. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology . 1997; 26 1621-1625
- 45 Tassopoulos N C, Volpes R, Pastore G. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Group. Hepatology . 1999; 29 889-896
- 46 Brunetto M R, Oliveri F, Coco B. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol . 2002; 36 263-270
- 47 Papatheodoridis G V, Manesis E, Hadziyannis S J. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol . 2001; 34 306-313
- 48 De Franchis R, Meucci G, Vecchi M. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med . 1993; 118 191-194
- 49 Bellentani S, Dal Molin G, Miglioli L. Natural history of HBV infection: a 9 years follow-up of the Dionysos cohort. J Hepatol . 2002; 36(Suppl 1) 228
- 50 Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm S W. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology . 1997; 26 1338-1342
- 51 Fattovich G, Giustina G, Sanchez-Tapias J. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol . 1998; 93 896-900
- 52 McMahon B J, Alberts S R, Wainwright R B, Bulkow L, Lanier A P. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska Native carriers. Arch Intern Med . 1990; 150 1051-1054
- 53 Huo T I, Wu J C, Lee P C. Sero-clearance of hepatitis B surface antigen in chronic carriers not necessarily implies a good prognosis. Hepatology . 1998; 28 231-236
- 54 Fattovich G, Brollo L, Giustina G. Natural history and prognostic factors of chronic hepatitis type B. Gut . 1991; 32 294-298
- 55 Ikeda K, Saitoh S, Suzuki Y. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation in 2215 patients. J Hepatol . 1998; 28 930-938
- 56 Mazzella G, Saracco G, Festi D. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol . 1999; 94 2246-2250
- 57 Fattovich G, Brollo L, Alberti A. Long term follow-up of anti-HBe positive chronic active hepatitis B. Hepatology . 1988; 8 1651-1654
- 58 Brunetto M R, Oliveri F, Rocca G. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology . 1989; 10 198-202
- 59 Kao J H, Chen P J, Lai M Y, Chen D S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology . 2000; 118 554-559
- 60 Chan H L, Tsang S W, Liew C T. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol . 2002; 97 406-412
- 61 Fattovich G, Tagger A, Brollo L. A Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis . 1991; 163 400-402
- 62 Fong T L, Di Bisceglie M A, Waggoner J G, Banks S M, Hoofnagle J H. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology . 1991; 14 64-67
- 63 Sagnelli E, Coppola N, Scolastico C. Virologic and clinical expression of reciprocal inhibitory effect of hepatitis B, C and delta viruses in patients with chronic hepatitis. Hepatology . 2000; 32 1106-1110
- 64 Gaeta G B, Stroffolini T, Chiaramonte M. Chronic hepatitis D: a vanishing disease?. <~>An Italian multicenter study. Hepatology . 2000; 32 824-827
- 65 Fattovich G, Boscaro S, Noventa F. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis . 1987; 155 931-935
- 66 Rosina F, Conoscitore P, Cuppone R. Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology . 1999; 117 161-166
- 67 Colin J F, Cazals-Hatem D, Loriot M A. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology . 1999; 29 1306-1310
- 68 Liaw Y F, Lin D Y, Chen T J, Chu C M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver . 1989; 9 235-241
- 69 Kato Y, Nakata K, Omagari K. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer . 1994; 74 2234-2238
- 70 Mazzella G, Accogli E, Sottili S. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol . 1996; 24 141-147
- 71 Ikeda K, Saitoh S, Suzuki Y. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. Cancer . 1998; 82 827-835
- 72 Fattovich G, Giustina G, Christensen E. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut . 2000; 46 420-426
- 73 Realdi G, Fattovich G, Hadziyannis S. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol . 1994; 21 656-666
- 74 Beasley R P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer . 1988; 61 1942-1956
- 75 Yu M W, Hsu F C, Sheen I S. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol . 1997; 145 1039-1047
- 76 McMahon B J, Bulkow L, Harpster A. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population based study. Hepatology . 2000; 32 842-846
- 77 Liaw Y F, Tai D I, Chu C M. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology . 1985; 90 263-267
- 78 Oon C J. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol . 1992; 31(Suppl 1) S137-S142
- 79 Fattovich G, Pantalena M, Zagni I. Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol . 2002; 97 2886-2895
- 80 Fattovich G, Giustina G, Schalm S W. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology . 1995; 21 77-82
- 81 Benvegnù L, Fattovich G, Noventa F. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer . 1994; 74 2442-2448
- 82 Chung H T, Lai C L, Lok A S. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology . 1995; 22 25-29
- 83 De Jongh E F, Janssen H LA, De Man A R. M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology . 1992; 103 1630-1635
- 84 Hui A Y, Chan H L, Leung N W. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol . 2002; 34 569-572
- 85 Hoofnagle J H, Di Bisceglie M A. The treatment of chronic viral hepatitis. N Engl J Med . 1997; 336 347-356
- 86 Evans A A, Fine M, London W T. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy. J Infect Dis . 1997; 176 845-850
- 87 Manesis E K, Hadziyannis S J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology . 2001; 121 101-109
- 88 Lampertico P, Viganò M, Iavarone M, Del Ninno E, Colombo M. Long-term outcome of patients with HBeAg-negative chronic hepatitis B treated with a 24-month course of interferon alfa. J Hepatol . 2001; 34(Suppl 1) 149
- 89 Niederau C, Heintges T, Lange S. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med . 1996; 334 1422-1427
- 90 EUROHEP: European Concerted Action on HBV-related Cirrhosis 2003. Updated analysis, data on file: Fattovich et al50
- 91 International Interferon-α Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet . 1998; 351 1535-1539
- 92 Lau D TY, Everhart J, Kleiner D E. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology . 1997; 113 1660-1667
- 93 Yao F Y, Terrault N A, Freise C, Maslow L, Bass N M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology . 2001; 34 411-416
- 94 Mutimer D. Beneficial effect of lamivudine for hepatitis B transplant recipients. Liver Transp . 2002; 8 440-442